In China, no oral GLP-1 drug has yet been approved specifically for obesity, though companies including Huadong Medicine and Hengrui Pharmaceuticals are advancing pipelines, suggesting the next phase of competition may shift from injectables to more convenient oral therapies
Zhang KL, Zhu WW, Wang SH, Gao C, Pan JJ, Du ZG, et al
None of which respond to transient peptide spikes
Whether the pill improves adherence "will heavily depend on whether insurers cover this new form of semaglutide and also the pricing for direct-to-consumer sales for this medication," says Gasoyan.
However, care must be taken when using HA, as it has been shown to regulate the TME and promote the malignant phenotype of cancer cells, and lead to multidrug resistance (Markowska et al., 2023)